NPPA panel fixes price of Dapagliflozin, Metformin FDC marketed by Lupin Medical Dialogues Team29 July 2021 12:51 PM GMTNew Delhi: With the popular antidiabetic drug, Dapagliflozin, going off-patent, the National Pharmaceutical Pricing Authority (NPPA) panel, giving bene...
Setback to AstraZeneca: Delhi HC rejects plea against 9 pharma firms over Dapagliflozin Medical Dialogues Team26 July 2021 10:42 AM GMTNew Delhi: In a major setback to AstraZeneca and its Indian subsidiary ,the Delhi High Court has dismissed AstraZeneca's plea against nine generic phar...
SGLT2 inhibitor dapagliflozin safe and effective in patients with advanced kidney disease: Study Hina Zahid21 July 2021 12:45 PM GMTThe effects of dapagliflozin in patients with stage 4 CKD are similar to effects in patients with mild to moderate CKD. USA: The benefits of SGLT2...
NPPA fixes price of 14 formulations including Diabetes drugs and antibiotics, Details Medical Dialogues Team20 July 2021 8:01 AM GMTNew Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority (NPPA), Ministry of Chemicals and Fertilizers, Government of India, h...
Glenmark gets CDSCO panel marketing nod to Remogliflozin, Teneligliptin FDC Medical Dialogues Team18 July 2021 6:00 AM GMTNew Delhi: In a major rejoice to Mumbai-based Glenmark Pharmaceuticals Limited, the Subject Expert Committee (SEC) of the Central Drugs Standard Contro...
Dapagliflozin reduces risk of new type 2 diabetes in CKD patients: Study Medha30 Jun 2021 3:30 AM GMTDelhi: Treatment with dapagliflozin in chronic kidney disease (CKD) patients significantly reduced the risk of new-onset type 2 diabetes (T2D), show...
Mankind Pharma launches Dapagliflozin brand Justoza for diabetes, heart failure, CKD ruchika23 Jun 2021 8:00 AM GMTNew Delhi: Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat Diabetes, Heart Failure and Chronic Kidney...
Adjuvant Therapy with Dapagliflozin bests Insulin Dose Escalation in Diabetes: Study MD Bureau15 Jun 2021 3:30 AM GMTNearly 1 in 4 patients with type 2 diabetes mellitus eventually require insulin therapy because of progressive deterioration of glycemic control. A...
Dapagliflozin improves kidney and cardiac function in cases of FSGS kidney disease: Study Hina Zahid10 Jun 2021 3:30 AM GMTSGLT2 inhibitors offer a promising new therapeutic option in the field of nephrology and are likely to be used more extensively in future, both in diab...
SGLT2 inhibitors improve biomarkers indicative of CVD risk in diabetes patients: Study Medha2 Jun 2021 4:00 AM GMTTurkey: Both dapagliflozin and empagliflozin significantly improve plasma atherogenic biomarkers (AIP and TyG indexes), an indicator of cardiovascular ...
Abbott, AstraZeneca terminate agreement for diabetes drug Dapagliflozin in India ruchika30 May 2021 4:45 AM GMTNew Delhi: Drug major AstraZeneca Pharma India on Friday said it has terminated its distribution agreements with Abbott Healthcare for type 2 diabetes ...
Sun pharma secures trademarks rights of diabetes drug Dapagliflozin under 3 brands from AstraZeneca ruchika29 May 2021 12:00 PM GMTNew Delhi: Drug major Sun Pharma on Friday said it has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and ...
